Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
OwnerTimothy R Willis, Ralph P. Stoneinventors
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.
Claims20
An ophthalmic suspension for delivery of at least one pharmaceutical ingredient to a patient in need thereof, the ophthalmic suspension comprising:
- a) an ophthalmic suspension vehicle comprising:
- i) an aqueous phase comprising water and one or more components selected from the group consisting of a wax ester, an anionic polar surfactant, an nonionic surfactant, a salt and a phosphate;
- and
- ii) an oil phase comprising at least one mineral oil and, optionally, at least one wax ester;
- and
- b) at least one pharmaceutical ingredient,
- wherein the ophthalmic suspension vehicle has an osmolality of from about 270 mOsmol/kg to about 315 mOsmol/kg, a zeta potential of from about −60 mV to about −110 mV, and an ionic mobility of from about −6 (μm/s)/(V/cm) to about −7.5 (μm/s)/(V/cm).
A method for delivering a predetermined amount of at least one pharmaceutical ingredient to a patient in need of treatment, the method comprising the step of:
- administering to an eye of the patient, an ophthalmic suspension comprising:
- a) an ophthalmic suspension vehicle comprising:
- i) an aqueous phase comprising water and one or more components selected from the group consisting of at least one wax ester, at least one anionic polar surfactant, at least one nonionic surfactant, at least one salt, and at least one phosphate;
- and
- ii) an oil phase comprising at least one mineral oil and, optionally, at least one wax ester;
- and
- b) at least one pharmaceutical ingredient,
- wherein the ophthalmic suspension exhibits a zeta potential of from about −60 mV to about −110 mV and an ionic mobility of from about −5.9 (μm/s)/(V/cm) to about −7.4 (μm/s)/(V/cm).
A method of increasing lipid layer thickness on a patient's eye in need of treatment, the method comprising the step of:
- administering to an eye of the patient, an ophthalmic suspension comprising:
- a) an ophthalmic suspension vehicle comprising:
- i) an aqueous phase comprising water and one or more components selected from the group consisting of at least one wax ester, at least one anionic polar surfactant, at least one nonionic surfactant, at least one salt, and at least one phosphate;
- and
- ii) an oil phase comprising at least one mineral oil and, optionally, at least one wax ester;
- and
- b) at least one pharmaceutical ingredient,
- wherein the ophthalmic suspension exhibits a zeta potential of from about −60 mV to about −110 mV and an ionic mobility of from about −5.9 (μm/s)/(V/cm) to about −7.4 (μm/s)/(V/cm).
Dependencies are inferred from the claim text.